Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells

Figure 2

PF-04691502 induces apoptosis via downregulation of Mcl-1 in bladder cancer cells (a) T-24 and 5637 cells were treated with the indicated doses of PF-04691502 for 24 h and then, cellular apoptosis was measured using flow cytometry. (b) T-24 and 5637 cells were treated with the indicated doses of PF-04691502 for 24 h and cellular lysates were subjected to western blot analysis. (c) T-24 and 5637 cells were treated with the indicated doses of PF-04691502 for 24 h and caspase-3 activities were measured. (d) T-24 and 5637 cells were treated with the indicated doses of PF-04691502 for 24 h and the levels of the specific proteins were measured using western blotting. (e) T-24 and 5637 cells were transfected as indicated for 12 h and then, the cells were treated with or without PF-04691502 for another 24 h and the levels of the specific proteins were measured using western blotting. (f) T-24 and 5637 cells were treated as described above, and cellular apoptosis was measured. (g) T-24 and 5637 cells were treated as described above, and cellular viabilities were measured. Data are representative of at least three independent experiments (; ).

(a)

(b)

(c)

(d)

(e)

(f)

(g)